« Back

Eliezer Katz, MD, FACS

Dr. Katz has served as Chief Medical Officer of Eledon since November 2023. He joined Eledon Pharmaceuticals from eGenesis where he served as Chief Medical Officer. Prior to eGenesis, Dr. Katz was Vice President of Clinical Development first at Viela Bio and then at Horizon Therapeutics following its acquisition of Vielo Bio. At Horizon and Viela Bio, Dr. Katz led the clinical development of inebilizumab in multiple autoimmune indications and oversaw the regulatory submission and approval of UPLIZNA®(inebilizumab). Prior to Viela Bio, Dr. Katz served as Senior Director of Clinical Development at MedImmune Inc. and Senior Director of Transplantation with the Medicine Development Group at Pfizer. Before joining industry, Dr. Katz spent two decades as a transplant surgeon. He was director of the abdominal transplantation division at Integris Baptist Medical Center in Oklahoma City, and an associate professor of surgery and the director of the liver transplantation division at the University of Massachusetts Medical Center, Worcester, MA. Dr. Katz earned his M.D. at Hadassah Hebrew University Medical School in Jerusalem.